CASI is a U.S. based pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, U.S., and throughout the world. We are a NASDAQ-listed company, with offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which substantially all of our operations are conducted.
Corporate Presentation - BIO CEO & Investor Conference
Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated,
Locally Advanced or Metastatic Triple-Negative Breast Cancer